[
    "The full protocol is available as an attachment.  ",
    "The following is a summary that is also found in the attached full protocol.",
    "Part 1: ",
    "1) Baseline assessments are taken the evening before dosing",
    "2) Subjects are given study medication after an overnight fast and 2 hours before their first meal.",
    "3) Part 1 includes 4 dose cohorts:  cohorts 1 and 2 consist of 4 subjects each, whereas Cohorts 3 and 4 will consist of 8 subjects each.",
    "4) Subjects are randomized at a 3 \\(active) to 1 \\(placebo) ratio. ",
    "5)",
    "Each subject receives a single dose of either 0.1 mg/kg \\(Cohort 1), 0.5 mg/kg \\(Cohort 2), 3 mg/kg \\(Cohort 3) or 10 mg/kg \\(Cohort 4) of tildrakizumab IV administered over 1 hour; a minimum of 48 hours will elapse between drug administration to subjects. ",
    "6) After an 8-week safety observation period, each subject in Part 1 \\(Cohorts 1 through 4) receives an additional two doses of tildrakizumab IV at 0.1, 0.5, 3, and 10 mg/kg, respectively, 4 weeks apart.",
    "7) On Day 2, safety assessments are performed and PK samples obtained. ",
    "8) Subjects receive Dose 2 on Day 56",
    "9) Subjects receive Dose 3 on Day 84",
    "10) Subjects have a closeout visit within 14 days of the last safety and PK assessment.",
    "Part 2 ",
    "1.",
    "Up to 40 subjects with psoriasis are enrolled in Part 2\r\n  2.",
    "Subjects are ",
    "Put into 2 dose cohorts \\(Cohorts 5 and 6). \r\n  ",
    "3.",
    "Subjects in Cohort 5 receive 3 doses of 3 mg/kg tildrakizumab IV given at Week 0, 4, and 8. \r\n  4.",
    "Subjects in Cohort 6 receive 3 doses of 10 mg/kg tildrakizumab IV given at Week 0, 4, and 8.\r\n  5.",
    "Subjects are randomized in a 3:1 ratio of active to placebo. \r\n  ",
    "6.",
    "Serum pharmacokinetic samples are obtained predose and at the intervals specified in the attached full protocol \r\n  7.",
    "Subjects receive Dose 2 and 3 of tildrakizumab during their visits on Days 28 and 56. \r\n  8.",
    "Subjects have a closeout visit within 14 days of the last PK assessment.\r\n  ",
    "9.",
    "A closeout visit will be scheduled within 14 days of the last PK assessment. \r\n  ",
    "Skin biopsy, pharmacokinetic, and safety details are provided in the attached full protocol"
]